Granulocyte-macrophage colony stimulating factor

DRUG2 trials

Sponsors

Tongji Hospital, Xiamen Amoytop Biotech Co., Ltd.

Conditions

Chronic Hepatitis BHepatitis B, Chronic

Phase 2

A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

CompletedNCT02332473

Xiamen Amoytop Biotech Co., Ltd.Chronic Hepatitis B

Start: 2014-06-30End: 2016-08-31Updated: 2017-01-25

Phase 3

A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)

Tongji HospitalHepatitis B, Chronic

Start: 2014-10-31End: 2019-06-30Target: 300Updated: 2016-08-15

Related Papers

Efficacy and safety of entecavir, peginterferon alfa-2b and GM-CSF combination therapy: the anchor randomized controlled trial.

2025-12-091 citations

High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With <scp>HBsAg</scp> Seroclearance

Alimentary Pharmacology & Therapeutics2025-07-162 citations

End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB

Journal of Hepatology2022-02-0892 citations